SES AUA 2025: Validation of PAM50 for Predicting Progression in Active Surveillance: Results from the Miami MAST Prospective Clinical Trial
SES AUA 2025, prostate cancer, Veracyte, Active Surveillance for prostate cancer, SPOP mutations, PTEN mutations, PAM50.